Renew Biotechnologies provides advanced genomic and epigenomic sequencing platforms for early and accurate disease detection. Their proprietary technologies identify clinically actionable biomarkers, enabling earlier intervention and personalized treatment strategies for conditions like neurodegenerative diseases and infectious agents.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases are diagnosed late, limiting the efficacy of interventions and patient outcomes. Current diagnostic methods often struggle to detect subtle, early-stage biomarkers, particularly for complex conditions like neurodegenerative diseases and infectious agents. This delay in detection hinders personalized treatment strategies and proactive disease management.
Solution
Renew Biotechnologies develops and deploys advanced genomic and epigenomic technologies designed for early and accurate disease detection. The company's portfolio focuses on identifying clinically actionable biomarkers through proprietary sequencing platforms, such as native-read sequencing and targeted long-read sequencing. These technologies are engineered for robustness, scalability, and high throughput, facilitating the translation of scientific discovery into clinical diagnostics. Renew's approach aims to bridge the gap between research and clinical application, enabling earlier intervention and improved patient care across various medical fields, including neurology, oncology, and infectious diseases.
Target Audience
The primary target audience includes biopharmaceutical companies, diagnostic laboratories, clinical research organizations, and healthcare providers seeking advanced tools for early disease detection and personalized medicine.
Features
- Native-read sequencing platforms for comprehensive genomic analysis.
- Targeted long-read sequencing for sensitive detection of specific biomarkers.
- Cell-of-origin sequencing to identify DNA biomarkers from dying neurons for neurodegenerative disease detection.
- Proprietary protocols for identifying pathogen-derived DNA for early infection detection.
- Specialized assays for women's health conditions, including endometriosis and gynecologic cancers.
- Forensic applications for distinguishing blood types in investigations.
- Scalable assay design optimized for regulatory approval pathways.
- High-throughput processing capabilities for clinical and research applications.